Madalina V Nastase1, Renato V Iozzo2, Liliana Schaefer3. 1. Pharmazentrum Frankfurt/ZAFES, Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt am Main, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. Electronic address: madalina.nastase@gmail.com. 2. Department of Pathology, Anatomy and Cell Biology, and the Cancer Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA. Electronic address: iozzo@kimmelcancercenter.org. 3. Pharmazentrum Frankfurt/ZAFES, Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt am Main, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. Electronic address: schaefer@med.uni-frankfurt.de.
Abstract
BACKGROUND: Small leucine-rich proteoglycans (SLRPs) are molecules that have signaling roles in a multitude of biological processes. In this respect, SLRPs play key roles in the evolution of a variety of diseases throughout the human body. SCOPE OF REVIEW: We will critically review current developments in the roles of SLRPs in several types of disease of the kidney and lungs. Particular emphasis will be given to the roles of decorin and biglycan, the best characterized members of the SLRP gene family. MAJOR CONCLUSIONS: In both renal and pulmonary disorders, SLRPs are essential elements that regulate several pathophysiological processes including fibrosis, inflammation and tumor progression. Decorin has remarkable antifibrotic and antitumorigenic properties and is considered a valuable potential treatment of these diseases. Biglycan can modulate inflammatory processes in lung and renal inflammation and is a potential target in the treatment of inflammatory conditions. GENERAL SIGNIFICANCE: SLRPs can serve as either treatment targets or as potential treatment in renal or lung disease. This article is part of a Special Issue entitled Matrix-mediated cell behaviour and properties.
BACKGROUND: Small leucine-rich proteoglycans (SLRPs) are molecules that have signaling roles in a multitude of biological processes. In this respect, SLRPs play key roles in the evolution of a variety of diseases throughout the human body. SCOPE OF REVIEW: We will critically review current developments in the roles of SLRPs in several types of disease of the kidney and lungs. Particular emphasis will be given to the roles of decorin and biglycan, the best characterized members of the SLRP gene family. MAJOR CONCLUSIONS: In both renal and pulmonary disorders, SLRPs are essential elements that regulate several pathophysiological processes including fibrosis, inflammation and tumor progression. Decorin has remarkable antifibrotic and antitumorigenic properties and is considered a valuable potential treatment of these diseases. Biglycan can modulate inflammatory processes in lung and renal inflammation and is a potential target in the treatment of inflammatory conditions. GENERAL SIGNIFICANCE: SLRPs can serve as either treatment targets or as potential treatment in renal or lung disease. This article is part of a Special Issue entitled Matrix-mediated cell behaviour and properties.
Authors: Marcus de Medeiros Matsushita; Luiz Fernando Ferraz da Silva; Mario Adriano dos Santos; Sandra Fernezlian; Jasmijn A Schrumpf; Peter Roughley; Pieter S Hiemstra; Paulo Hilário Nascimento Saldiva; Thais Mauad; Marisa Dolhnikoff Journal: J Pathol Date: 2005-09 Impact factor: 7.996
Authors: A Hildebrand; M Romarís; L M Rasmussen; D Heinegård; D R Twardzik; W A Border; E Ruoslahti Journal: Biochem J Date: 1994-09-01 Impact factor: 3.857
Authors: R Merline; S Lazaroski; A Babelova; W Tsalastra-Greul; J Pfeilschifter; K D Schluter; A Gunther; R V Iozzo; R M Schaefer; L Schaefer Journal: J Physiol Pharmacol Date: 2009-10 Impact factor: 3.011
Authors: W A Border; N A Noble; T Yamamoto; J R Harper; Y u Yamaguchi; M D Pierschbacher; E Ruoslahti Journal: Nature Date: 1992-11-26 Impact factor: 49.962
Authors: Thomas N Wight; Charles W Frevert; Jason S Debley; Stephen R Reeves; William C Parks; Steven F Ziegler Journal: Cell Immunol Date: 2016-12-23 Impact factor: 4.868
Authors: Achilleas D Theocharis; Spyros S Skandalis; Thomas Neill; Hinke A B Multhaupt; Mario Hubo; Helena Frey; Sandeep Gopal; Angélica Gomes; Nikos Afratis; Hooi Ching Lim; John R Couchman; Jorge Filmus; Ralph D Sanderson; Liliana Schaefer; Renato V Iozzo; Nikos K Karamanos Journal: Biochim Biophys Acta Date: 2015-03-28
Authors: Patricia G Wilson; Joel C Thompson; Meghan H Yoder; Richard Charnigo; Lisa R Tannock Journal: J Lipid Res Date: 2017-09-14 Impact factor: 5.922